ALLMedicine™ Multiple Myeloma Center
Research & Reviews 9,719 results
https://doi.org/10.1038/s41408-021-00577-2 10.1182/blood-2007-10-078022 10.1038/nrc2189 10.1182/blood-2007-10-116129 10.1146/annurev-med-112017-091045 10.1200/JCO.2015.61.2267 10.1200/JCO.2005.04.242 10.7326/0003-4819-115-12-931 10.1038/leu.2009.174 10.1007/s00277-018-3316-7 10.3324/haematol.2016.145078 10.1002/ajh.24891 10.1111/bjh.14701 10.1200/JCO.2009.25.5356 10.1046/j.1365-2141.1999.01244.x 10.3324/haematol.2012.065698 10.1016/S1470-2045(14)70442-5 10.1016/S1470-2045(19)30309-2 10.1016/S1470-2045(17)30189-4 10.1182/blood-2011-06-361386 10.1182/blood-2009-03-213280 10.1158/1078-0432.CCR-15-0396 10.2967/jnumed.112.106500 10.1016/0021-9681(60)90137-5 10.1016/S1470-2045(16)30206-6 10.1038/leu.2014.230 10.1182/blood-2018-04-842880 10.1038/s41467-017-00296-y 10.3390/ijms20051248 10.1182/blood-2017-03-774422 10.1182/blood-2016-01-631200
Blood Cancer Journal; Cho HJ, Jung SH et. al.
Dec 3rd, 2021 - In multiple myeloma (MM), a high number of focal lesions (FL) detected using positron emission tomography/computed tomography (PET/CT) was found to be associated with adverse prognosis. To design a new risk stratification system that combines the ...
https://doi.org/10.1038/s41408-021-00580-7 10.1016/S0140-6736(20)30183-5 10.1056/nejmoa2002032 10.1016/j.chest.2020.04.010 10.1158/2643-3230.bcd-20-0102 10.1182/blood.2020008150 10.1182/blood-2008-12-194241 10.1182/blood-2008-12-195008 10.1016/s1470-2045(14)70442-5 10.1056/nejmoa054494 10.1016/s0140-6736(10)60482-5 10.1111/j.1600-0609.1998.tb01075.x 10.3324/haematol.2011.054015 10.1182/blood-2009-11-252072 10.1182/blood-2012-07-445304 10.1016/j.bcmd.2020.102481 10.4065/84.8.685 10.1056/nejmoa2006100 10.1038/s41408-021-00480-w
Blood Cancer Journal; Rognvaldsson S, Eythorsson E et. al.
Dec 3rd, 2021 - Multiple myeloma (MM) patients have increased risk of severe coronavirus disease 2019 (COVID-19) when infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Monoclonal gammopathy of undetermined significance (MGUS), the precurso...
https://doi.org/10.1001/jamaoncol.2021.5942
JAMA Oncology; Terpos E, Rajkumar SV et. al.
Dec 3rd, 2021 - Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination.|2021|Terpos E,Rajkumar SV,Leung N,|
https://clinicaltrials.gov/ct2/show/NCT04557098
Dec 3rd, 2021 - Study record NCT03145181 is Phase 1 part of this study and study record NCT04557098 is Phase 2 part of this study.
https://clinicaltrials.gov/ct2/show/NCT03652064
Dec 3rd, 2021 - This study will evaluate participants with newly diagnosed multiple myeloma (MM) for whom hematopoietic stem cell transplant is not planned as initial therapy. The data available from other available studies suggests that addition of daratumumab w...
Guidelines 33 results
https://doi.org/10.1016/j.annonc.2020.11.014
Annals of Oncology : Official Journal of the European Soc... Dimopoulos MA, Moreau P et. al.
Feb 8th, 2021 - Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.|2021|Dimopoulos MA,Moreau P,Terpos E,Mateos MV,Zweegman S,|diagnosis,epidemiology,therapy,
https://doi.org/10.6004/jnccn.2020.0057
Journal of the National Comprehensive Cancer Network : JN... Kumar SK, Callander NS et. al.
Dec 8th, 2020 - Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. This manuscript discusses the management of patients with solitary plasmacytoma, smoldering multiple myeloma, ...
https://doi.org/10.1016/j.kint.2020.07.012
Kidney International; Małyszko J, Bamias A et. al.
Dec 6th, 2020 - The bidirectional relationship between cancer and chronic kidney disease (CKD) is complex. Patients with cancer, particularly those with hematological malignancies such as multiple myeloma and lymphoma, are at increased risk of developing acute ki...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781094
Physical Therapy; Jeevanantham D, Rajendran V et. al.
Sep 26th, 2020 - Individuals with multiple myeloma (MM) often have reduced functional performance due to the cancer itself or as a direct side effect of cancer treatments. Physical therapy is a part of cancer rehabilitation; however, no guidelines are available to...
https://doi.org/10.1200/JCO.18.02096
Journal of Clinical Oncology : Official Journal of the Am... Mikhael J, Ismaila N et. al.
Apr 2nd, 2019 - To provide evidence-based recommendations on the treatment of multiple myeloma to practicing physicians and others. ASCO and Cancer Care Ontario convened an Expert Panel of medical oncology, surgery, radiation oncology, and advocacy experts to con...
Drugs 142 results see all →
Clinicaltrials.gov 759 results
https://clinicaltrials.gov/ct2/show/NCT04557098
Dec 3rd, 2021 - Study record NCT03145181 is Phase 1 part of this study and study record NCT04557098 is Phase 2 part of this study.
https://clinicaltrials.gov/ct2/show/NCT03768960
Dec 3rd, 2021 - The purpose of this study is to demonstrate the safety profile of daratumumab in routine clinical practice when given as monotherapy in Indian participants with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome in...
https://clinicaltrials.gov/ct2/show/NCT03652064
Dec 3rd, 2021 - This study will evaluate participants with newly diagnosed multiple myeloma (MM) for whom hematopoietic stem cell transplant is not planned as initial therapy. The data available from other available studies suggests that addition of daratumumab w...
https://clinicaltrials.gov/ct2/show/NCT04634552
Dec 3rd, 2021 - Multiple myeloma is a malignant plasma cell disorder characterized by osteolytic lesions, increased susceptibility to infections, hypercalcemia, and renal failure. Talquetamab is a humanized immunoglobulin G4 proline, alanine, alanine (IgG4PAA) bi...
https://clinicaltrials.gov/ct2/show/NCT02086552
Dec 3rd, 2021 - PRIMARY OBJECTIVES: I. To assess the complete response (CR) rate with lenalidomide and sonidegib (LDE225) maintenance following an upfront single autologous stem cell transplant (SCT). SECONDARY OBJECTIVES: I. To assess the toxicity of lenalidomid...
News 1,818 results
https://www.medpagetoday.com/infectiousdisease/covid19/95968
Dec 2nd, 2021 - Note that some links may require registration or subscription. Donald Trump tested positive for COVID-19 days before the first presidential debate against Joe Biden, according to his chief of staff at the time and other former aids; Trump denounce...
https://www.onclive.com/view/dr-rosko-on-disparities-within-clinical-trials-in-multiple-myeloma
Nov 23rd, 2021 - Ashley E. Rosko, MD, oncologist, associate professor, Department of Internal Medicine, The Ohio State University (OSU), medical director, Oncogeriatric Program, The OSU Comprehensive Cancer Center–James, discusses disparities within clinical trial...
https://www.onclive.com/view/dr-lee-on-defining-smoldering-multiple-myeloma
Nov 22nd, 2021 - Sarah S. Lee, MD, physician, Seattle Cancer Care Alliance, assistant professor, Division of Medical Oncology, University of Washington School of Medicine, assistant member, Clinical Research Division, Fred Hutchinson Cancer Research Center, discus...
https://www.onclive.com/view/mortality-rate-associated-with-covid-19-breakthrough-cases-remains-high-in-hematologic-malignancies
Nov 18th, 2021 - Although mortality rates in patients with hematologic cancers who develop breakthrough COVID-19 cases after vaccination are high, there has been a significant decrease in incidence since vaccines have become available, according to preliminary dat...
https://www.onclive.com/view/btk-inhibitors-pi3k-inhibitors-and-car-t-cell-therapy-shake-up-hematologic-malignancies-armamentarium
Nov 15th, 2021 - BTK inhibitors, PI3K inhibitors, and CAR T-cell therapies have changed the treatment landscape of many hematologic malignancies, said Harry Paul Erba, MD, PhD, who added that the evolving paradigms underscore the need for individualized decision m...
